Myeloma patients who become refractory to immunomodulatory agents (IMiDs) and bortezomib have poor survival, with limited therapeutic options. Pomalidomide has shown improved survival and good tolerability in this patient cohort in clinical trials, but real world data are scarce. We retrospectively analysed all patients treated with pomalidomide at five UK centres between 2013 and 2016. Of 85 patients identified, 70 had sufficient information for response assessments. Median age was 66 years , 96Á5% were refractory to IMiDs, 72Á9% were refractory to both an IMiD and bortezomib and 92Á9% were refractory to their last treatment. Of 45 patients with fluorescence in situ hybridization results 64% had adverse risk, 19 patients (22Á4%) had an estimated glomerular filtration rate <45 ml/min. Grade ≥3 non-haematological toxicities occurred in 42Á4%, and grade ≥3 neutropenia and thrombocytopenia in 38% and 24% respectively, but only 18Á8% had dose reductions. The overall response rate was 52Á9%. At a median follow-up of 13Á2 months, median progression-free survival was 5Á2 months [95% confidence interval (CI) 4Á150-6Á238], and median overall survival was 13Á7 months (95% CI 11Á775-15Á707). No significant difference was seen in response, survival or tolerability by renal function, age or cytogenetic risk. This real-world data support the results seen in published clinical trials.
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Despite recent improvements in overall survival, myeloma remains an incurable disease with a median overall survival of 7 years . The therapeutic options remain limited for patients who relapse after or become refractory to bortezomib and immunomodulatory agents (IMiDs; thalidomide or lenalidomide), with a median overall survival (OS) of 9 months and only 3 months if no further treatment is given (Kumar et al, 2012) .
Such patients have an increasing symptom burden related to advanced disease and prior therapies (Mols et al, 2012; Boland et al, 2013) hence the need for therapies providing good disease control while maintaining quality of life. Pomalidomide is a second generation IMiD, with efficacy demonstrated in end stage multiple myeloma in both phase 1 and 2 clinical trials (Richardson et al, 2013; Richardson et al, 2014) . The pivotal MM-003 trial was a large multicentre randomised trial of 455 patients refractory to both lenalidomide and bortezomib, comparing pomalidomide (4 mg OD for 21/28 days) plus low dose dexamethasone (40 mg weekly) with high dose dexamethasone alone. Overall response rates (ORRs) were 32% versus 11%. With a median follow-up of 15Á4 months, pomalidomide/dexamethasone demonstrated a significant benefit in progressionfree survival (PFS; median 4 months vs. 1Á9 months, P < 0Á0001) and OS (median 13Á1 vs. 8Á1 months, P = 0Á009) despite significant crossover in the high dose dexamethasone arm (San Miguel et al, 2013) . A recent phase 3b trial (MM-010) confirmed the safety and efficacy research paper of pomalidomide and low dose dexamethasone in these patients (Cancer Drugs Fund, 2015) , restricting National Health Service access to pomalidomide in the UK to the clinical trial setting.
Pomalidomide has been shown to be relatively well tolerated in patients with advanced/end-stage myeloma. Although myelosuppression is common, with neutropenia being the most common side effect, febrile neutropenia has been reported to be relatively infrequent (Lacy et al, 2011) .
Clinical trial data may not always reflect real world clinical practice and outcomes, particularly when dealing with a cohort of patients with such advanced stage disease, many of whom have significant disease or treatment-related co-morbidities, making delivery of recommended treatment challenging. We thus carried out a retrospective analysis of patients receiving pomalidomide in current UK myeloma practice, to describe the outcomes as well as tolerability of pomalidomide in a real world clinical setting, in comparison with those from current published clinical trials.
Methods

Patients and treatment details
All patients who had received or were currently receiving treatment with pomalidomide at five major UK centres between August 2013 and March 2016 were identified from electronic chemotherapy records. Data on patient demographics, side effects and response to treatment were collected using a standardised proforma. To be included in response assessments, patients had to have measurable disease as defined by International Myeloma Working Group (IMWG) guidelines (Kumar et al, 2016) and have completed at least one cycle of pomalidomide with repeat biomarkers performed. Treatment consisted of 28-day cycles of pomalidomide (taken daily on days 1-21) plus dexamethasone (on days 1, 8, 15 and 22), plus or minus a third agent.
Assessments
Adverse events were graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Categories of response and progression were identified using IMWG criteria .
Fluorescence in situ hybridization (FISH), where performed, was carried out on selected CD138 + plasma cells using standard probes . High risk FISH was defined as del(17p), 1q gain or t(4;14) in line with IMWG risk stratification in multiple myeloma (Chng et al, 2014) .
Statistical analysis
Survival was estimated using Kaplan-Meier method. Data analysis was performed with IBM SPSS for Mac, version 22 (IBM Corp., Armonk, NY, USA). Curves were plotted using GraphPad Prism, version 7 (GraphPad Software, La Jolla, CA, USA). Comparisons between groups were estimated using the log rank method. Univariate Cox regression was used to assess the impact of baseline characteristics on PFS and OS. P-values < 0Á05 were considered statistically significant.
Results
A total of 85 patients who received treatment with pomalidomide were identified. Of these, 70 (82%) were able to be included in response analyses. Of the remaining 15 patients for whom response could not be assessed, 7 did not complete a single cycle of treatment, 5 completed 1 cycle but did not have repeat biomarkers, 2 completed 2 cycles but did not have repeat biomarkers, and the final patient completed 9 cycles but had non-secretory disease. Baseline patient characteristics, treatment and toxicity data and survival for all 85 patients are reported below. Further data regarding response and sub-group survival analyses are reported for the group of 70 patients in whom response data are available.
Patient characteristics including previous therapy
Demographic details are given in Table I . Median patient age was 66 years (range 40-89), 15 (17Á6%) patients were aged over 75 years and 48 (56Á5%) were over 65 years of age. Renal function was assessed using estimated glomerular filtration rate (eGFR); 32 patients (37Á6%) had an eGFR less than 60 ml/min, and 19 patients (22Á4%) had an eGFR less than 45 ml/min. Results of FISH analysis were available in 45 cases (52Á9%). Of these, 29 patients (64%) had adverse cytogenetics, 20 patients (44%) if 1q gain was excluded, and 14 (31%) patients had 17p deletion.
Details of previous treatments and responses are given in Table II . It is noteworthy that the majority of patients (96Á5%) were refractory to one or more IMiD, and 72Á9% were refractory to both an IMiD and bortezomib. Seventynine patients (92Á9%) were refractory to their last treatment.
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Pomalidomide therapy
Details regarding median dose, length of treatment and dose reductions are given in Table III. Seventy patients (82Á4%) started therapy on pomalidomide plus dexamethasone (doublet therapy). The remaining 15 patients (17Á6%) were started on pomalidomide/dexamethasone plus a third agent (triple therapy). Of those started on doublet therapy, 19 patients had a third agent added during treatment (22Á4% of total). The third agent(s) given either up front or added-in later were clarithromycin (23), cyclophosphamide (9), carfilzomib (1) and bortezomib (1).
Toxicity and tolerability of pomalidomide therapy
Grades 3-4 non-haematological toxicities occurred in 36 out of 85 patients (42Á4%): lower respiratory tract infection, 14 (16Á5%), neutropenic sepsis, 7 (8Á2%) and acute kidney injury, 6 (7Á1%), were the most common. Rates of fatigue and venous thromboembolism were low. Grades 3-4 neutropenia occurred in 32 patients (38%) and thrombocytopenia in 20 patients (Table IV) . Six patients died during the first cycle: one with progressive disease (PD) and sepsis, two with neutropenic sepsis (one had a strangulated hernia), two with renal failure in the context of progressive disease and one from pneumonia. One further patient died on treatment, of lower respiratory tract infection. Of those six patients, 5/6 were male, 4/6 were aged over 70 years and 5/6 had a GFR < 45 ml/min.
Disease response and survival
The median follow-up for the whole group of 85 patients was 13Á2 months. Median PFS was 4Á5 months [95% confidence interval (CI) 2Á837-6Á104] and median OS 9Á7 months (95% CI 5Á078-14Á252) (Fig 1A,C) . We also analysed outcomes for the group of 70 response-assessable patients (median follow up 13Á2 months). Of this group, 67 patients had progressed or died (95Á7%), 49 of who had died (70%). Median PFS was 5Á2 months (95% CI 4Á150-6Á238) and median OS was 13Á7 months (95% CI 11Á775-15Á707) (Fig 1B,D) . Overall response rates (in response assessable patients) was 52Á9% [5Á7% very good partial response (VGPR), 47Á1% partial response (PR) and 38Á6% stable disease (SD)] (Table V) . No patients achieved complete response. Median time to best response was 1 month, and median duration of response was 4 months.
All correlates of treatment outcomes are reported for the response assessable group of 70 patients.
Effect of renal impairment
Twelve patients (17Á1%) had eGFR <45 ml/min. Among these patients, the median starting dose of pomalidomide was 4 mg and five patients received less than 4 mg as a starting dose. In this group of patients, ORR was 50%; one patient achieved VGPR, five patients achieved PR (41Á7%), four patients SD and two patients had PD. By comparison, amongst patients with eGFR ≥45 (n = 58), the ORR was 53Á4%, with three patients achieving VGPR, and 28 patients (48Á3%) achieving PR. Thus, disease responses were similar for both groups of patients.
On univariate analysis, eGFR <45 ml/min did not significantly influence PFS or OS. Median PFS in patients with eGFR <45 ml/min was 3Á7 months, compared with 5Á2 months in patients with eGFR ≥45 ml/min [Hazard ratio (HR) = 0Á952, 95% CI 0Á496-1Á827, P = 0Á882). Median OS in patients with eGFR <45 ml/min was 7Á4 months, compared with 14Á1 months in those with an eGFR ≥45 ml/min (HR = 1Á224, 95% CI 0Á592-2Á531, P = 0Á586) (Fig 2) . Finally there was no difference in rates of either haematological or non-haematological toxicity between these two groups of patients.
Effect of genetic risk
In FISH did not significantly influence OS either (median OS of 10Á9 months vs. 8Á4 months for standard risk, HR = 1Á223, 95% CI 0Á557-2Á688, P = 0Á616) (Fig 2) . The presence of 17p deletion did not significantly influence PFS or OS (median PFS of 2Á3 months vs. 6Á2 months for patients without this abnormality, HR 1Á194, 95% CI 0Á568-2Á507, P = 0Á640, and OS 9Á7 months vs. 12Á9 months, HR = 1Á314, 95% CI 0Á609-2Á836, P = 0Á486).
Influence of patient age
In patients over the age of 65 years (37, 52Á9%), the ORR was 54Á1%, with two patients achieving VGPR, and 18 patients (48Á6%) obtaining PR. In comparison, amongst patients aged 65 years or less (n = 33), the ORR was 51Á5%, two patients achieved VGPR, and 15 patients (45Á5%) obtained a PR. Median PFS for the over 65 group was 5Á5 months versus 4Á5 months in younger patients (HR = 1Á013, 95% CI 0Á624-1Á643, P = 0Á960), and OS was comparable in both groups (Fig 2) . Patients over the age of 65 years did not seem to experience more toxicities.
Nine patients were aged over 75 (12Á9%). Median PFS was 7Á2 months for age >75 years versus 5Á1 months for age ≤75 (HR = 0Á685, 95% CI 0Á325-1Á444, P = 0Á321). Seven out of nine patients aged over 75 years were still alive at time of data analysis.
Influence of depth and duration of response
Median PFS was 6Á7 months in patients who achieved at least PR, compared with 4Á5 months for SD and 1Á4 months for PD, while median OS was 17Á7 months in patients who achieved at least PR, compared with 13Á1 months for SD and 3Á6 months for PD. More striking was the effect of durability of response. For patients with durability of response of at least 4 months, median PFS was 11Á7 months and OS 23Á0 months. In contrast, in patients whose response lasted less than 4 months or who did not respond, median OS was 9Á3 months (Fig 3) .
No other factors were found to significantly influence PFS (sex, increasing age, time from diagnosis to receiving pomalidomide, double versus triple therapy at start of therapy). Increasing time from diagnosis to receiving pomalidomide approached significance (HR 0Á908, 95% CI 0Á820-1Á005, P = 0Á062). No other factors were found to significantly influence OS (Table SI) .
Outcome of relapse
Thirty patients went on to receive further treatment after relapse on pomalidomide (42Á9%). The most common next treatment was bendamustine/thalidomide/dexamethasone (13 patients, 43Á3% of 30). Table SII provides further details.
Discussion
We describe a real-world experience of patients receiving pomalidomide for relapsed/refractory multiple myeloma in the United Kingdom. The characteristics of the patients described in this cohort are broadly similar to those in published clinical trials (San Miguel et al, 2013; Dimopoulos et al, 2016) . Patients in our cohort were heavily pre-treated; 72Á9% were refractory to both an IMiD and bortezomib, and 93% were refractory to their last treatment. In addition, 44% of patients tested had adverse genetics (excluding 1q gain) and 37Á6% had an eGFR of <60 ml/min.
Disease response in assessable patients (n = 70) in our cohort was 52Á9% compared with 31Á4% in MM-003 and 32Á6% in MM-010. Disease-free survival (DFS) in the same group (5 months) and OS (13 months) were remarkably similar to the results of published clinical trials (San Miguel et al, 2013; Dimopoulos et al, 2016) . In MM-003 and MM-010 trials (San Miguel et al, 2013; Dimopoulos et al, 2016) , the PFS was 4 and 4Á6 months respectively, with OS of 13Á1 and 11Á9 months respectively. When survival outcomes were analysed for the entire cohort of 85 patients in our study, median PFS was 4 months and OS was a little shorter, at 9 months. This probably reflects the extremely poor outcomes of a minority of patients who did not complete their first cycle of treatment. Of the six patients who died in the first cycle, four died of infection, four were over 70 years old and five had renal impairment. No statistically significant difference in response, survival or tolerability was seen in key patient groups, including those with moderate renal impairment, adverse cytogenetics and of older age. Taken as a whole, our findings are an important addition to the body of evidence for the benefit of pomalidomide therapy in this patient population.
Pomalidomide is metabolised extensively in the liver and only 2% is excreted in the urine (Hoffmann et al, 2013) . Hence, no dose modification for renal failure should be necessary as recently reported from the ongoing MM-013 trial (Ramasamy et al, 2015) . The MM-003 trial excluded patients with a creatinine clearance of less than 45 ml/min, however, the 31% of patients with a creatinine clearance of less than 60 ml/min did not have an inferior PFS or OS and pomalidomide was safe and well tolerated . A subsequent pooled analysis of patients from three trials (MM-003, MM-010 and MM-002) reported comparable response rates and PFS but shorter OS in the 355 patients with creatinine clearance of 30-60 ml/min, when compared with patients without renal impairment (Siegel et al, 2016) . In our series, median OS was not statistically inferior in those with renal impairment (7Á4 vs. 14Á1 months), although this may be due to small patient numbers. We found no increased toxicity in patients who had an eGFR <45 ml/min, plus response rates and PFS were similar. The final results of the on-going MM-013 trial (NCT02045017) examining the safety and pharmacokinetics of pomalidomide in more severe renal impairment are awaited.
Patients with adverse cytogenetic abnormalities generally have poor outcomes, however in the MM-003 trial, PFS and OS benefits of pomalidomide therapy were seen regardless of the cytogenetic risk group . In our patient group, 63% of patients with genetic information had adverse FISH features, but this did not appear to influence their outcomes (response, PFS and OS) . Some emerging data suggest that pomalidomide has activity in adverse genetic risk disease. In the phase II study, in combination with dexamethasone, ORR was 74% in high risk patients (del17p, t(4;14) and t(14;16) compared with 63% in the whole group (Lacy et al, 2009) , while patients with del(17p) in the Intergroupe Francophone du My elome (IFM) 2010-2002 study fared well in the pomalidomide arm (Leleu et al, 2015) . Such observations contribute to our increasing understanding of the interaction of particular drugs with the biology of specific genetic abnormalities, and provide a rationale for further studies investigating the use of pomalidomide earlier in the treatment pathway for patients with high risk disease.
One of the challenges in managing relapsed refractory MM is in the older and frailer patients, however, subgroup analysis of many randomized studies suggest that these patients can also benefit from new drugs. In the MM-003 trial, safety and efficacy benefits of pomalidomide-dexamethasone were not influenced by age (San Miguel et al, 2013) . Patients in our cohort were of similar age range to that in the MM-003 study, with 15 patients (17Á6%) >75 years and 48 patients (56Á5%) >65 years. We observed no influence of age on response rates, PFS, OS or tolerability.
Depth and sustainability of response were two important predictors of survival benefit in our patient cohort. Achievement of PR or better was associated with a DFS and OS benefit. Importantly, patients who achieved SD still appeared to derive a survival benefit with an OS of 13Á1 vs. 3Á6 months in those with PD. Post hoc analysis of the MM-003 trial data has also shown this relationship between depth of response and survival Moreau et al, 2016) . In our cohort, patients with sustained disease response of at least 4 months had an estimated survival of nearly 2 years, suggesting that achieving disease stability increases the opportunity to receive further treatment at progression.
Pomalidomide plus dexamethasone was well tolerated in this heavily pre-treated population. Haematological toxicities were relatively infrequent, as were infections, including neutropenic sepsis (8%). These rates compare favourably with reported adverse events in the pomalidomide arm of MM-003, and in the MM-010 study (San Miguel et al, 2013; Dimopoulos et al, 2016) . However, it is important to highlight that although overall rates of infection were low, four out of six patient deaths during the first cycle were related to sepsis. This real life data further adds to the published evidence that pomalidomide has a good safety profile and is well tolerated. The low incidence of gastro-intestinal toxicity is particularly notable in an oral agent, and would support testing of combinations of pomalidomide with other antimyeloma agents.
Several studies of pomalidomide in triplet combinations in the relapsed refractory setting have reported higher ORRs with acceptable toxicity (Allan et al, 2013) , for example in combination with cyclophosphamide (Larocca et al, 2013; Baz et al, 2016) and carfilzomib (Shah et al, 2015) . In our series, the addition of a third agent, either at start of therapy or during treatment, was not associated with superior outcomes, but results are likely to be influenced by patient bias and selection in this small series, and the results of prospective randomized studies are awaited. Other combinations being explored in clinical trials include those with marizomib , bortezomib , ricolinostat (Raje et al, 2015) and daratumumab (Chari et al, 2015) .
Therapeutic options for patients at this late stage of the treatment pathway continue to expand. Newer agents recently licensed for this patient group include histone deacetylase (HDAC) inhibitors, such as panobinostat, in combination with bortezomib and monoclonal antibodies like the first-in-class anti-CD38 antibody, daratumumab plus other agents, such as elotuzumab, ixazomib and carfilzomib (Nooka et al, 2015; Lonial et al, 2016) . Across the board, ORRs to these new agents are around 30-40%, with DFS of 3-4 months Lonial et al, 2016) . It is clear however, that despite the overall dismal outlook for this patient group, the subset that are able to respond to a new drug fare remarkably well. This is borne out by the recently published results of the SIRIUS study with daratumumab, where patients achieving PR had an estimated survival that was not reached, at a median follow up of 14 months . We urgently need better biomarkers in order to identify which patients are likely to respond to specific therapies, leading to improved utilization of limited healthcare resources, and minimization of treatment-related toxicities for our patients.
In summary, we report our real-world experience of patients receiving pomalidomide for relapsed/refractory myeloma, with outcomes (response, survival, tolerability) similar to those in published clinical trials. Importantly, although patient numbers are small, benefit is seen in those with moderate renal impairment, adverse cytogenetics and older age. Recently a small retrospective analysis of 39 patients treated with pomalidomide was published, reporting remarkably similar outcomes to our own, including good tolerability (Sriskandarajah et al, 2017) . Our data provide confirmatory support for exploring pomalidomide-based combination therapy both in the relapsed setting, and more upfront, especially in patients with adverse genetics.
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